SCHEMBL4672449

SCHEMBL4672449

O=C(Cc1csc(Cc2ccccc2F)n1)C(=O)c1nc[nH]n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
TLR7 Q9NYK1 1/20 0.37
HTR3A P46098 1/20 0.35
RAB9A P51151 4/20 0.34
NPC1 O15118 3/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
SLC40A1 Q9NP59 1/20 0.34
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
ELOVL1 Q9BW60 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
PDE5A O76074 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675278 0.92 LMNA (0.36) LMNAHPGDTLR7HTR3ARAB9A
SCHEMBL4676248 0.85 HDAC1 (0.47) LMNARAB9ANPC1MAPTALDH1A1
SCHEMBL4675179 0.83 LMNA (0.39) LMNAHPGDTLR7RAB9ANPC1
SCHEMBL4676214 0.83 SLC40A1 (0.36) LMNAHPGDRAB9ANPC1MAPT
SCHEMBL4674383 0.83 LMNA (0.40) LMNATLR7RAB9ANPC1MAPT
SCHEMBL4674110 0.82 HDAC1 (0.43) RAB9ANPC1MAPTGAASMN1; SMN2
SCHEMBL4676076 0.81 AR (0.33) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL4671667 0.80 HDAC1 (0.37) LMNAGAASLC40A1HDAC1HDAC6
SCHEMBL4674195 0.79 ABL1 (0.35) LMNAHPGDRAB9ANPC1SMN1; SMN2
SCHEMBL4677066 0.79 PTPN1 (0.35) LMNAHPGDRAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 LMNA 659/4885HPGD 2816/4885TLR7 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.